Nephros (NEPH) Liabilities and Shareholders Equity (2010 - 2026)

Nephros has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $13.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 17.12% year-over-year to $13.8 million; the trailing twelve-month figure through Mar 2026 stood at $52.9 million (up 19.0% YoY), and the FY2025 full-year result was $13.6 million, up 21.69% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $13.8 million, up from $13.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $15.5 million in Q1 2022, with the low at $10.4 million in Q2 2023.
• Average Liabilities and Shareholders Equity over 5 years is $12.1 million, with a median of $11.4 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity tumbled 37.68% in 2022 and advanced 27.55% in 2025.
• Tracing NEPH's Liabilities and Shareholders Equity over 5 years: stood at $11.0 million in 2022, then grew by 7.84% to $11.9 million in 2023, then decreased by 5.49% to $11.2 million in 2024, then climbed by 21.69% to $13.6 million in 2025, then grew by 1.12% to $13.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $13.8 million (Q1 2026), $13.6 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.

Peer Comparison